Pharma Industry Tells Patent Office to Go Slow on AI (Correct)

The US patent office shouldn’t yet develop broad policy around the use of AI because the technology’s use is still in its early stages, Pharmaceutical Research and Manufacturers of America said Monday.

“Indeed, use of AI within the pharmaceutical industry is a recent phenomenon, and the use of such tools are highly experimental and fragmented,” Vice President of IP and Law David E. Korn and Assistant General Counsel John E. Nappi said in comments to the PTO.

The trade group, representing US research companies, submitted comments to the US Patent and Trademark Office alongside other pharmaceutical stakeholders. The PTO asked ...